Sasho Klekovski, director of the Foundation for the Protection of the Elderly (FSSH), announced the availability of palbociclib, a new drug approved for use with 142 cancer patients. The drug’s annual cost is estimated at 7,000 patients. Klekovski stated that the drug is currently available in the market and is slated for wider availability in 2026.
During a conference on cancer treatment at the Radiotherapy and Oncology Clinics, Klekovski reported positive results from patient trials. The drug is projected to be accessible to 50 patients annually, with a plan to increase this to 80 patients in the 2025 implementation. The FSSH anticipates the drug’s market entry will occur in 2025, serving a patient population of 142 annually at a cost of 7,000 patients per year.
